BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31315892)

  • 1. Expression of the type 3 InsP
    Guerra MT; Florentino RM; Franca A; Lima Filho AC; Dos Santos ML; Fonseca RC; Lemos FO; Fonseca MC; Kruglov E; Mennone A; Njei B; Gibson J; Guan F; Cheng YC; Ananthanarayanan M; Gu J; Jiang J; Zhao H; Lima CX; Vidigal PT; Oliveira AG; Nathanson MH; Leite MF
    Gut; 2019 Sep; 68(9):1676-1687. PubMed ID: 31315892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
    Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear Factor, Erythroid 2-Like 2 Regulates Expression of Type 3 Inositol 1,4,5-Trisphosphate Receptor and Calcium Signaling in Cholangiocytes.
    Weerachayaphorn J; Amaya MJ; Spirli C; Chansela P; Mitchell-Richards KA; Ananthanarayanan M; Nathanson MH
    Gastroenterology; 2015 Jul; 149(1):211-222.e10. PubMed ID: 25796361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma.
    Dos Santos ML; França A; Lima Filho ACM; Florentino RM; Diniz PH; Oliveira Lemos F; Gonçalves CAX; Coelho VL; Lima CX; Foureaux G; Nathanson MH; Vidigal PVT; Leite MF
    Oncol Lett; 2022 Jan; 23(1):32. PubMed ID: 34966448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium signalling from the type I inositol 1,4,5-trisphosphate receptor is required at early phase of liver regeneration.
    Oliveira AG; Andrade VA; Guimarães ES; Florentino RM; Sousa PA; Marques PE; Melo FM; Ortega MJ; Menezes GB; Leite MF
    Liver Int; 2015 Apr; 35(4):1162-71. PubMed ID: 24814243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inositol 1,4,5-trisphosphate receptor type 3 plays a protective role in hepatocytes during hepatic ischemia-reperfusion injury.
    Lima Filho ACM; França A; Florentino RM; Dos Santos ML; de Oliveira Lemos F; Missiaggia DG; Fonseca RC; Gustavo Oliveira A; Ananthanarayanan M; Guerra MT; de Castro Fonseca M; Vidigal PVT; Lima CX; Nathanson MH; Fatima Leite M
    Cell Calcium; 2020 Nov; 91():102264. PubMed ID: 32957029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.
    Cubero FJ; Zhao G; Nevzorova YA; Hatting M; Al Masaoudi M; Verdier J; Peng J; Schaefer FM; Hermanns N; Boekschoten MV; Grouls C; Gassler N; Kiessling F; Muller M; Davis RJ; Liedtke C; Trautwein C
    J Hepatol; 2015 Jan; 62(1):140-9. PubMed ID: 25173965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4).
    Rodrigues MA; Gomes DA; Cosme AL; Sanches MD; Resende V; Cassali GD
    Biomed Pharmacother; 2022 Jan; 145():112403. PubMed ID: 34798470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma.
    Feng T; Dzieran J; Gu X; Marhenke S; Vogel A; Machida K; Weiss TS; Ruemmele P; Kollmar O; Hoffmann P; Grässer F; Allgayer H; Fabian J; Weng HL; Teufel A; Maass T; Meyer C; Lehmann U; Zhu C; Mertens PR; Gao CF; Dooley S; Meindl-Beinker NM
    Clin Sci (Lond); 2015 Jun; 128(11):761-74. PubMed ID: 25602745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein arginine methyl transferase 1- and Jumonji C domain-containing protein 6-dependent arginine methylation regulate hepatocyte nuclear factor 4 alpha expression and hepatocyte proliferation in mice.
    Zhao J; Adams A; Roberts B; O'Neil M; Vittal A; Schmitt T; Kumer S; Cox J; Li Z; Weinman SA; Tikhanovich I
    Hepatology; 2018 Mar; 67(3):1109-1126. PubMed ID: 29023917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
    Yan Q; Zhang ZF; Chen XP; Gutmann DH; Xiong M; Xiao ZY; Huang ZY
    Int J Oncol; 2008 May; 32(5):1057-63. PubMed ID: 18425332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP.
    Xie R; Xu J; Wen G; Jin H; Liu X; Yang Y; Ji B; Jiang Y; Song P; Dong H; Tuo B
    J Biol Chem; 2014 Jul; 289(27):19137-49. PubMed ID: 24847054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deranged hepatocyte intracellular Ca
    Ali ES; Rychkov GY; Barritt GJ
    Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth.
    He N; Park K; Zhang Y; Huang J; Lu S; Wang L
    Gastroenterology; 2008 Mar; 134(3):793-802. PubMed ID: 18325392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.
    Li H; Zhang M; Linghu E; Zhou F; Herman JG; Hu L; Guo M
    Clin Epigenetics; 2018 Nov; 10(1):137. PubMed ID: 30400968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.
    Guo Y; Peng Y; Gao D; Zhang M; Yang W; Linghu E; Herman JG; Fuks F; Dong G; Guo M
    Clin Epigenetics; 2017; 9():116. PubMed ID: 29075359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
    Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
    Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.